Jack Ball's departure as CEO of Seattle-based Amnis Corporation, revealed last week, was the result of a difference in opinion over the aggressiveness with which the company should market its flagship ImageStream 100 imaging cytometer, CBA News has learned.

"The company really decided to take a different path to commercialization that didn't require the skill sets that I brought in," Ball said. "We just sort of differed on what was the best way to move forward commercially. I would say that [Amnis] wants a more low-key approach to commercialization."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.